Our R&D Approach

Our research mission is simple: innovations that improve the quality of life of people everywhere. That motivation keeps us at the forefront of the Healthcare, Life Science and Electronics industries.

Healthcare R&D

Our research scientists are working tirelessly to develop groundbreaking medicines and technologies to treat everything from cancer and multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more

Life Science R&D

R&D focus: Reimagining new ways to meet the needs of our customers

Innovation is at the core of the value that we deliver to our customers. Our Life Science scientists and engineers tirelessly work to develop novel approaches to new and age-old challenges.We show our commitment to innovation through our financial investments as well. Every year, we invest around €400 million in R&D, supporting new innovations designed to meet our customers' most unmet needs – from antibodies to water purification systems. Innovation is visible when new products hit the shelves and when new services emerge. 

The ability to innovate is the core of our culture across all three of our businesses; Science & Lab Solutions, Process Solutions and Life Science Services. Learn more

Electronics R&D

R&D focus: Keeping the world’s Electronics on the cutting edge

Our Electronics business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more

Related News

View All News
  1. Press Releases

    Future Insight Prize 2024 Awarded to Johns Hopkins University’s Lauren Gardner

    We awarded Lauren Gardner, representing Johns Hopkins University, Baltimore, USA, with the Future Insight Prize 2024 worth 500.000 € today.

    2024/07/10

  2. Press Releases

    Merck KGaA, Darmstadt, Germany, Provides Update on Xevinapant Program in Locally ...

    Merck KGaA, Darmstadt, Germany, today announced the discontinuation of the Phase III randomized TrilynX study.

    2024/06/24

  3. Press Releases

    EMD Electronics highlights Innovations in Materials IntelligenceTM

    EMD Electronics will showcase innovation addressing the semiconductor ecosystem’s greatest opportunities and challenges in R&D, sustainability, and workforce development through collaboration

    2024/06/18

Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis and infertility to colds and pains. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more